## **Product Data Sheet**

#### PE anti-mouse / rat CD29

**Catalog # / Size:** 1111035 / 50 μg

 $1111040 / 200 \mu g$ 

Clone:  $HM\beta1-1$ 

**Isotype:** Hamster IgG

**Immunogen:** Purified mouse VLA-4 ( $\alpha_4\beta_1$ ,

CD49d/CD29)

Reactivity: Mouse,Rat

**Preparation:** The antibody was purified by affinity


chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and

unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide.

Concentration: 0.2



Lou rat bone marrow cells stained with HM $\beta$ 1-1 biotin, then detected with Sav-PE

## **Applications:**

**Applications:** Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is  $\leq 0.25$  microg per  $10^6$  cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.


Application Notes:

Additional reported applications (for the relevant formats) include:

immunoprecipitation1,

immunohistochemistry4 of acetone-fixed frozen sections, *in vitro* blocking of the adhesion of mouse tumor cell lines to extracellular matrix proteins and *in vitro* inhibition of T cell proliferative responses1, and *in vivo* inhibition of neutrophil migration2. The LEAF  $^{\text{TM}}$  purified antibody (Endotoxin <0.1 EU/ $\mu$ g, Azide-Free, 0.2  $\mu$ m filtered) is recommended for functional assays

(Cat. No. 102210).



C57BL/6 mouse splenocytes stained with HM $\beta$ 1-1 PE

Application References:

- 1. Noto K, et al. 1995. Int. Immunol. 7:835.
- 2. Ridger VC, et al. 2001. J. Immunol. 166:3484.
- 3. Jia W, et al. 2005. Blood 106:3854. PubMed
- 4. Economopoulou M, et al. 2005. Blood 106:3831.
- 5. Lawson BR, et al. 2007. J. Immunol. 178:5366.
- 6. Eisenmann KM, et al. 2007. J. Biol. Chem. doi:10.1074/jbc.M703243200. PubMed
- 7. Hayashi Y, et al. 2008. Am J Physiol Gastrointest Liver Physiol. 294:G778.

<u>PubMed</u>

- 8. Kim DT, et al. 2008. Blood 111:2929. PubMed
- 9. Hayashi Y, et al. 2008. J Pharmacol Exp Ther. 326:523. PubMed
- 10. Carlson TR, et al. 2008. Development. 135:2193. PubMed
- 11. Sangaletti S, et al. 2008. Cancer Res. 68:9050. (Block) PubMed
- 12. Zuba-Surma EK, et al. 2008. J Mol Cell Cardiol. 44:865. PubMed
- 13. Zheng Z, et al. 2012. Biochem Biophys Res Commun. 428:309. PubMed
- 14. Diaferia GR, et al. 2013. Development. 140:3360. PubMed
- 15. Liang CZ, et al. 2013. Acta Biomater. 9:9423. PubMed
- 16. Simonetti G, et al. 2013. J Exp Med. 210:2287. PubMed
- 17. Weckbach LT, et al. 2014. Blood. 123:1887. PubMed
- 18. Toda S, et al. 2014. Blood. 123:3963. PubMed

#### **Description:**

CD29 is a 130 kD protein, also known as integrin  $\beta_1$ , VLA- $\beta$  chain, or GPIIa. It is a member of the integrin family, expressed broadly on leukocytes, endothelial cells, smooth muscle, and epithelial cells. In association with CD49a-f, CD29 forms the VLA-1 through VLA-6 complexes, respectively. It plays an important role in cell-cell or cell-matrix interaction. The HMß1-1 antibody reacts with both mouse and rat CD29. It is able to block cell adhesion and inhibit T cell proliferation.

# Antigen References:

1. Noto K, et al. 1995. Int. Immunol. 7:835.